CD192抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD192 mouse mAb (green) and negative control (red).    

  
  

CD192. also known as CCR2 (C-C chemokine receptor type 2), is a G protein-coupled receptor primarily expressed on monocytes, macrophages, and certain T-cell subsets. It binds to chemokines such as CCL2 (MCP-1), CCL7. and CCL12. playing a critical role in mediating immune cell migration to sites of inflammation, infection, or injury. CCR2 is implicated in various pathological conditions, including chronic inflammation, autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis), atherosclerosis, and cancer metastasis.

CD192 antibodies are tools designed to target and modulate CCR2 activity. They are used in research to study receptor-ligand interactions, immune cell trafficking, and disease mechanisms. Therapeutically, CCR2-blocking antibodies have been explored to inhibit pro-inflammatory pathways or disrupt the tumor microenvironment by limiting monocyte infiltration. For instance, in cancer, CCR2 inhibition may reduce tumor-associated macrophage recruitment, potentially suppressing tumor growth and metastasis. Conversely, some antibody-based strategies aim to enhance immune responses by redirecting immune cells to diseased tissues.

Despite promising preclinical results, clinical translation faces challenges, including redundancy in chemokine signaling and off-target effects. Current efforts focus on optimizing antibody specificity, affinity, and delivery to improve therapeutic efficacy. CD192 antibodies remain pivotal in both understanding CCR2 biology and developing targeted therapies for inflammation-related and oncologic disorders.